Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine

Cancer Gene Therapy

Volumn 9, Issue 3, 2002, Pages 243-253

  Carsana, Marilisa ^a   Tragni, Gabrina ^a   Nicolini, Gabriella ^a   Bersani, Ilaria ^a   Parmiani, Giorgio ^a   Anichini, Andrea ^a   Sun, Yuan Sheng ^b   Möller, Peter ^b   Schadendorf, Dirk ^b   Sensi, Maria Luisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Gene transfer; IL 7; Melanoma; T lymphocytes; T cell receptor; Tumor vaccination

Indexed keywords

CANCER VACCINE; INTERLEUKIN 7; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR CELL VACCINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD; ATP-BINDING CASSETTE TRANSPORTERS; CANCER VACCINES; DNA PRIMERS; FEMALE; GENE REARRANGEMENT, T-LYMPHOCYTE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-7; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SKIN NEOPLASMS; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; VACCINATION;

EID: 85047698246     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700435     Document Type: Article

References (46)

1. Human tumor antigens for cancer vaccine development
2. Cell-based vaccination against melanoma - Background, preliminary results, and perspective
3. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
4. Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
5. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma
6. Phase II trial for vaccination with tyrosinase peptides and GM-CSF in melanoma
7. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
8. + hematopoietic progenitor cells
9. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte derived dendritic cells expands specific cytotoxic T cells and induce regression of some metastases in advanced stage IV melanoma
10. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2-transduced allogeneic melanoma cells
11. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
12. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
13. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status - A clinical phase I study
14. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
15. T-cell repertoire diversity and clonal expansions in normal and clinical samples
16. Analysis of TCR usage in human tumors: A new tool for assessing tumor-specific immune responses
17. In situ T cells in melanoma
18. Evidence for in situ amplification of cytotoxic T lymphocytes with antitumor activity in a human regressive melanoma
19. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: Tumor-infiltrating lymphocytes overexpress in vivo the TCR β chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone
20. Direct evidence to support the immunosurveillance concept in a human regressive melanoma
21. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine
22. Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts
23. High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition
24. Analysis of the T-cell immune response in renal cell carcinoma: Polarization to type 1-like differentiation pattern, clonal T cell expansion and tumor-specific cytotoxicity
25. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion
26. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation
27. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma
28. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ
29. Phenotypic analysis of antigen-specific T lymphocytes
30. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
31. An expanded peripheral T cell population to a cytotoxic (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
32. + T cells
33. In vivo selective expansion of a tumor-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with genemodified autologous tumor cells
34. Increased non-MHC-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells
35. High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR
36. Translation of a retained intron in tyrosinase-related protein (TRP)-2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
37. An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-29/β1-24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction
38. Human T-cell receptor variable gene segment families
39. Immunohistochemical analysis of the T-cell receptor β-chain variable region expressed by T lymphocytes infiltrating primary human melanoma
40. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas
41. Sequence analysis of the human α/β T-cell receptor CDR3 region
42. TCR β-chain variable region-driven selection and massive expansion of HLA-class I-restricted anti-tumor CTL lines from HLA-A*0201 melanoma patients
43. Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: Dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture
44. Evidence of oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymphnode lymphocytes
45. T-cell receptor CDR3-size distribution analysis to evaluate specific T-cell response to cancer vaccine
46. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line